

AMENDMENTS TO THE CLAIMS

- 1-4. (Canceled)
5. (Previously Presented) A method of identifying a human patient suspected of having a lung adenocarcinoma comprising:
- obtaining a cell or tissue sample of cells or tissue suspected of comprising the lung adenocarcinoma from the patient;
 - exogenously expressing RB2/p130 gene in said sample; and
 - assaying for expression of a gene set in said cell or tissue sample, wherein down-regulation of transcription of the gene set by at least a two fold in said sample is indicative of possible presence of lung adenocarcinoma, said gene set selected from the group consisting of PCNA, MKK3, B-MYB, CCNF, BUB1B, PLK, NIK, KNSL2, PCSK7, CCNB2, GPRK6, HCFC1, PFAS, DNMT1, KPNA2, STK15, TIEG, BUB1 ELK1, UMPK, PMI, CAMKK2, GSK3B, HADHSC, POLD1, NOL1, EMK1, GRP-R, XRCC3, CHK, MAGEA3/6, PPM1G, TRAF5, ABCF2, TEAD4, PIM1, CCND1, CDR2, PSMB2, RAF1, and combinations of any thereof.
6. (Previously Presented) The method of claim 5, wherein the gene set is PCNA, MKK3, B-MYB, and NIK.
7. (Currently Amended) The method of claim 5, wherein the gene set is RAF-1, PIM1, ~~CyeD4~~, GRPR, and KPNA2, ~~and CyeB2~~.
8. (Withdrawn) The method of claim 5, wherein the gene set is B-MYB, PCSK7, STK15, ELK1, NOL1, MAGEA3/6, PIM1, CCND1, CDR2, and RAF1
9. (Currently Amended) The method of claim 5, wherein the gene set is CCNF, BUB1B, PLK, ~~[[,]]~~ KNSL2, PCSK7, CCNB2, GPRK6, HCFC1, PFAS, DNMT1, STK15, TIEG, BUB1 ELK1, UMPK, PMI, CAMKK2, GSK3B, HADHSC, POLD1, NOL1, EMK1, XRCC3, CHK, MAGEA3/6, PPM1G, TRAF5, ABCF2, TEAD4, CCND1, CDR2 and PSMB2.
10. (Canceled)

11. (Currently Amended) The method of claim 5, wherein the step of assaying ~~involves~~ comprises the use of an oligonucleotide microarray assay to determine the expression of the gene set.

12. (Previously Presented) The method of claim 5, wherein the patient is post-treatment for a non-small cell lung cancer.

13-20. (Canceled)